Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Objective: We performed a meta-analysis of randomized double-blinded placebo controlled trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major depressive disorder (MDD) including treatment resistant depression (TRD) and major depression with suicide ideation (MDSI).Methods: Mean change in total scores on Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to different time-points were our primary outcome measure.Secondary efficacy measures included rate of remission of depression and resolution of suicidality.Results: Eight DB-RCTs (seven published and one un-published) covering 1,488 patients with MDD were included.Esketamine more significantly improved MADRS total scores than placebo starting from 2-4 hours after the first administration (standardized mean difference, -0.41 [95% CI, -0.58 to -0.25], p < 0.00001), and this superiority maintained until end of double-blinded period (28 days).Sub-group analysis showed that superior antidepressant effects of esketamine over placebo in TRD and MDSI was observed from 2-4 hours, which was maintained until 28 days.Resolution of suicide in MDSI was also greater for esketamine than for placebo at 2-4 hours (OR of 2.04, 95% CIs, 1.37 to 3.05, p = 0.0005), but two groups did not statistically differ at 24 hours and day 28.Total adverse events (AEs), and other common AEs including dissociation, blood pressure increment, nausea, vertigo, dysgeusia, dizziness, and somnolence were more frequent in esketamine than in placebo group.Conclusion: Esketamine showed rapid antidepressant effects in patients with MDD, including TRD and MDSI.The study also suggested that esketamine might be associated with rapid anti-suicidal effects for patients with MDSI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Besides low remission and response rate, delayed onset of efficacy is another important limitation of conventional antidepressants [4,5].”
BackgroundKessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · cited 1×
“Major depressive disorder (MDD) is a common debilitating disease with a lifetime prevalence of 15−20%, and it is known to cause severe functional impairment [1,2].”
BackgroundEpidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“4% of patients with MDD actually commit or complete suicide [6,7].”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 1×
“Esketamine is a nonselective, noncompetitive antagonist at the N -methyl-D-aspartate (NMDA) receptor which modulates glutamatergic transmission [12].”
BackgroundPopova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 4×
“Four [15,16,20,21] studies used flexible doses while other four [17,19,29,30] used fixed doses of intranasal esketamine.”
BackgroundInfluentialMelsen, W. G., Bootsma, M. C. J., Rovers, M. M., & Bonten, M. J. M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12494 · Cited by 776 · cited 1×
“In terms of heterogeneity, we used I(2) statistic and evaluated what degree of variance between studies can be attributed to actual differences between the studies rather than to chance [28].”
MethodDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 17×
“In terms of patients with TRD, MADRS improvement was significantly more superior in intranasal esketamine group than in placebo group from 2−4 hours (SMD, −0.67 [95% CI, −1.16 to −0.17], p = 0.008) to 24 hours (SMD, −0.48 [95% CI, −0.82 to −0.13], p = 0.007), week 1 (SMD, −0.27 [95% CI, −0.42 to −0.12], p = 0.0003), a…”
BackgroundInfluentialCanuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Cited by
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
Esketamine combined with SSRI or SNRI for treatment-resistant depression
Del Casale, A., Spirito, S., Arena, J. F., Preissner, S., Borro, M., Gentile, G., Modesti, M. N., Preissner, R., Ferracuti, S., & Simmaco, M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0200 · Cited by 23
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
Metadata
- Authors
- Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M.
- Venue
- Clinical Psychopharmacology and Neuroscience
- Published
- 2021-05-31
- Volume
- 19
- Issue
- 2
- Pages
- 341-354
- ISSN
- 1738-1088 (ISSN-L)
- 2093-4327
- OpenAlex
- W3156926718
- Cited by
- 52
- References
- 20
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis. https://app.cochat.ai/papers/10.9758/cpn.2021.19.2.341
- The paper
- Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021). Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis. Clinical Psychopharmacology and Neuroscience. https://doi.org/10.9758/cpn.2021.19.2.341
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.